Recursion Pharmaceuticals, Inc. (RXRX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Naheed Kurji | President of Canada | -- | -- | -- |
| Mr. Imran Haque | Senior Vice President of AI & Digital Sciences | -- | -- | -- |
| Ganesh Kumar Jagannathan | Chief Information Security Officer & VP of IT | -- | -- | -- |
| Dr. Najat Khan | Chief R&D Officer, Chief Commercial Officer & Director | -- | -- | -- |
Recursion Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 500
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Corporate Governance
Recent Events
- Apr 23, 2024DEFA14A: Proxy StatementsSee Full Filing
- Apr 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 07, 20248-K: Corporate Changes & Voting MattersSee Full Filing